ライフサイエンスコーパス: cytokeratin-19

1 1, cyclin G1, alpha smooth muscle actin, and cytokeratin 19).

2 and in some cells the liver stem cell marker cytokeratin 19.

3 solute copy numbers of the epithelial marker cytokeratin 19.

4 e cell surface in cells with lower levels of cytokeratin 19.

5 specifically apical cytokeratin, presumably cytokeratin 19.

6 MA and fibronectin expression and suppressed cytokeratin-19.

7 igen, epithelial cell adhesion molecule, and cytokeratin-19.

8 Cytokeratin 19-, A6- and alpha-fetoprotein-positive cell

9 Some of these genes (cytokeratin 19, alpha smooth muscle actin, and kappa cas

10 (Col1A1), matrix metalloproteinase 2 (Mmp2), cytokeratin 19, alpha-smooth muscle actin (alpha-SMA), c

11 In addition, injured hepatocytes can express cytokeratin 19 and AE1, which normally are biliary inter

12 and expressed the biliary epithelial markers cytokeratin 19 and carbonic anhydrase IV.

13 o activation of duct-specific genes, such as cytokeratin 19 and cytokeratin 20, suggesting that alter

14 tudy we confirmed the apical distribution of cytokeratin 19 and expanded that observation to other ep

15 n were evaluated by immunohistochemistry for cytokeratin 19 and Ki-67.

16 press albumin and stained more intensely for cytokeratin 19 and laminin.

17 atures with mature bile duct epithelium (AE1/cytokeratin 19 and type IV collagenase positive) or HEP

18 +)/cytokeratin-19(+) or alpha-fetoprotein(+)/cytokeratin-19(-) and contain all of the normal liver re

19 nomas revealed strong expression of keratin, cytokeratin 19, and cytokeratin 20 in the cytoplasm of a

20 (7 days in culture) express cytokeratin 18, cytokeratin 19, and vimentin.

21 multaneously positive for alpha-fetoprotein, cytokeratin-19, and c-kit, indicating their progenitor p

22 epithelial marker E-CADHERIN, biliary marker CYTOKERATIN-19, and mesenchymal markers VIMENTIN and alp

23 xpress these stem cell markers together with cytokeratin 19, another putative stem cell marker in the

24 e microscopy the milk protein lactoferrin or cytokeratin 19, both markers of differentiation expresse

25 Cells that were still positive for cytokeratin-19 but actively producing type I collagen we

26 nce of known stem/progenitor markers such as cytokeratin 19, c-Kit, EpCAM, and activated Wnt-beta-cat

27 f sex determining region Y-box (SOX)9(+) and cytokeratin 19(+) cells but fewer features of hepatocyte

28 ptase polymerase chain reaction (RT-PCR) for cytokeratin 19 (CK-19) may be useful in the management o

29 d a quantitative system for the detection of cytokeratin 19 (CK-19) transcripts using reverse transcr

30 (AFP), gamma-glutamyl transpeptidase (GGT), cytokeratin 19 (CK-19), OC.2, and OV-6, all known marker

31 ence confocal microscopy was performed using cytokeratin 19 (CK-19; biliary cell marker) with either

32 by morphometry of liver sections stained for cytokeratin-19 (CK-19) and by proliferating cellular nuc

33 ed BEC, as well as each cell line, expressed cytokeratin-19 (CK-19), epithelial cell adhesion molecul

34 r antigen (PCNA)-positive cholangiocytes and cytokeratin-19 (CK-19)-positive ducts.

35 naling occupying an alpha-fetoprotein (AFP)+/cytokeratin-19 (CK-19)-positive progenitor cell niche fo

36 s human epithelial antigen-125 (HEA-125) and cytokeratin-19 (CK-19).

37 umin, and cells expressing AFP, albumin, and cytokeratins-19 (CK-19).

38 s were serially sectioned, immunostained for cytokeratin 19 (CK19), and sequentially photographed.

39 yte nuclear factor-3beta (HNF-3beta), GATA4, cytokeratin 19 (CK19), transthyretin, and alpha-fetoprot

40 of persistent nodules and all HCCs expressed cytokeratin 19 (CK19), whereas 14% of remodeling nodules

41 mponent of the active NF-kappa B complex, in cytokeratin 19 (CK19)-positive epithelial cells of ER-ne

42 epidermal growth factor receptor (EgfR) and cytokeratin 19 (CK19).

43 (DCAMKL-1), Lgr5, CD133, alpha-fetoprotein, cytokeratin-19 (CK19), Lin28, and c-Myc.

44 roteins used clinically for staging disease (cytokeratin 19 [CK19]), identifying cancer stem cells (e

45 sociated with cholangiocyte differentiation (cytokeratin 19, connexin 43, integrin beta4, and gamma-g

46 mine the threshold levels of mammaglobin and cytokeratin 19 correlating with metastasis greater than

47 Immunohistochemistry with ductal (keratin, cytokeratin 19, cytokeratin 20), acinar (chymotrypsin),

48 The amount of cytokeratin 19 expression was related to clinicopatholog

49 001) and with the progenitor subtype of HCC (cytokeratin 19 expression, P = 0.031).

50 and the induction of alpha-actin and loss of cytokeratin 19 expression.

51 IBDM was detected by cytokeratin-19 expression and proliferation by Ki-67 imm

52 several known genes, including mammaglobin, cytokeratin 19, fibronectin, and hair-specific type II k

53 uamous cell carcinoma antigen (P = .03), and cytokeratin 19 fragment antigen 21-1 (P = .01) were mark

54 Baseline plasma carcinoembryonic antigen/cytokeratin 19 fragments biomarker signature was associa

55 ly one protein, and phosphorylation released cytokeratin 19 from the complexes.

56 analysis identified four of these clones as cytokeratin 19, GATA-3, CD24 and glutathione-S-transfera

57 in urothelial cells under the control of the cytokeratin 19 gene (CK19) regulatory elements.

58 els of epithelial cell adhesion molecule and cytokeratin 19 gene messenger RNAs.

59 tures and immunohistochemical markers (PD-1, cytokeratin 19, glutamine synthetase, and beta-catenin e

60 omas showed strong expression of keratin and cytokeratin 19 in all neoplastic cells, expression of cy

61 nterestingly, colocalization of alphaSMA and cytokeratin-19 in bile duct epithelium was observed, sug

62 positive for the stem/progenitor cell marker cytokeratin-19, indicating that several HCC-associated a

63 s expressed cholangiocyte markers, including cytokeratin 19, integrin beta4, and aquaporin-1, but not

64 s of junctional E-cadherin localization, and cytokeratin 19 (K19) expression.

65 es the clinical significance of detection of cytokeratin 19 (K19) in the bone marrow of patients with

66 eatic ductal cells (PDCs) were purified from cytokeratin 19 (K19)-Ki-RAS(G12V) transgenic mice and co

67 ons positive for the progenitor cell marker, cytokeratin-19 (Krt-19) and characterized by a higher pr

68 hat increased LC3B was located mainly in the cytokeratin 19-labeled ductular reaction (DR) in human c

69 increased, whereas those for E-cadherin and cytokeratin 19 (markers for the epithelial phenotype) we

70 thioate oligodeoxy nucleotides that targeted cytokeratin 19 mRNA enabled us to obtain confluent monol

71 ymph nodes (six) had more than 106 copies of cytokeratin 19 mRNA per microg total RNA.

72 2 and hepatic nuclear factor-4alpha, but not cytokeratin 19 or carbonic anhydrase IV.

73 Rat ED14 FLSPC are alpha-fetoprotein(+)/cytokeratin-19(+) or alpha-fetoprotein(+)/cytokeratin-19

74 ssical oval cell markers (alpha-fetoprotein, cytokeratin-19, OV-1 antigen, a6 integrin, and connexin

75 The ductal blast-like cells do not express cytokeratin 19, oval cell antigen 270.38, or actin immun

76 ors were strongly immunoreactive for biliary cytokeratin 19, p185neu, and cyclooxygenase-2.

77 complexes containing both gamma-tubulin and cytokeratin 19, p34(cdc2) phosphorylated only one protei

78 We determined whether cytokeratin-19 positive (K19(+)) cholangiocytes give ris

79 Enhanced NF-kappaB staining of cytokeratin 19-positive bile ducts and proliferating duc

80 tein within parenchyma and the appearance of cytokeratin 19-positive bile ductule-like cells (oval ce

81 Cytokeratin 19-positive cells are detected surrounding t

82 re shown by immunofluorescence to consist of cytokeratin 19-positive duct cells and hormone-positive

83 In vivo, the DDC-stimulated number of cytokeratin-19-positive cells in the liver of wild-type

84 taste buds at adulthood as a result of fewer cytokeratin-19-positive cells.

85 ional cells, forming duct-like structures of cytokeratin-19-positive cells.

86 e NRF2 pathway accompanied the regression of cytokeratin-19-positive nodules, suggesting that activat

87 can largely be accounted for by addition of cytokeratin-19-positive taste bud cells.

88 f markers expressed by bile duct epithelium (cytokeratin 19), produce TGFalpha and acidic FGF and ass

89 derations, there is parallel activity of the cytokeratin 19 promoter in the stem cell region of the g

90 e generated a novel mouse model in which the cytokeratin 19 promoter, specifically active in pancreat

91 re designed not to amplify either of the two cytokeratin 19 pseudogenes.

92 This downregulation of cytokeratin 19 resulted in (a) decrease in the number of

93 ed 2-3 min after palpation (P<0.01) by human cytokeratin 19 RT-PCR of extracted RNA from 300 microl o

94 gon, and somatostatin, as well as peripheral cytokeratin-19 staining.

95 mpression cytology (PAS, cytokeratin 12, and cytokeratin 19) staining were performed in the central c

96 evidence of micrometastases had the highest cytokeratin 19 transcription level in a first lymph-node

97 Median copy number of cytokeratin 19 transcription was significantly higher (>

98 Expression of cytokeratin 19 (up to 1.1 x 10(5) copies per microg RNA)

99 e-oligonucleotide-mediated downregulation of cytokeratin 19, using two different antisense sequences,

100 reactive for cytokeratin 18 and negative for cytokeratin 19, vimentin, and alpha-smooth muscle actin

101 ibroblastic RPE (35 days in culture) express cytokeratin 19, vimentin, and alphaSMA.

102 was never expressed, but in some mice, human cytokeratin 19 was expressed, which may indicate bile du

103 Transcription of cytokeratin 19 was found at a low level in just one of 3

104 fic genes (gamma-glutamyl transpeptidase and cytokeratin 19) was similar among the three subpopulatio